OrbiMed Capital GP VI LLC, Director at Oric Pharmaceuticals, Inc. (ORIC), sold 132,404 shares at $27.72 ($3.7M) on 2021-03-16, disclosed to the SEC on 2021-03-18.
Scheduled sale ($3.7M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.72 | 41,353 | $1.1M | 31.0% |
| 2 | $27.72 | 41,353 | $1.1M | 31.0% |
| 3 | $28.43 | 18,790 | $534K | 14.4% |
| 4 | $28.43 | 18,790 | $534K | 14.4% |
| 5 | $28.03 | 6,059 | $170K | 4.6% |
| 6 | $28.03 | 6,059 |
| $170K |
| 4.6% |
| Total | $27.95 avg | 132,404 | $3.7M | 100% |
| Filing → |
| IRON | SELL | 2025-03-12 | $32.4M | — | Filing → |
| SCPH | BUY | 2024-08-15 | $2.0M | — | Filing → |
| NPCE | SELL | 2024-04-18 | $435K | — | Filing → |